DMOG
Inhibits prolyl hydroxylase domain-containing proteins / Inhibits PHD or prolyl hydroxylase domain-containing proteins, activating HIF1α1,2 and inhibiting JMJD2A (IC50 = 2.5 μM)3. Displays neuroprotective effects. Inhibits neuronal cell death caused by neurotrophin deprivation4. Prevents activation of the ATR/CHK1/p53 pathway and suppresses apoptosis induced by DNA damage5.
Biochemicals & reagents
89464-63-1
Dimethyloxalylglycine
1) Asikainen et al. (2005), Activation of hypoxia-inducible factors in hyperoxia through prolyl 4-hydroxylase blockade in cells and explants of primate lung; Proc. Natl. Acad. Sci. USA, 102 10212 2) Jaakkola et al. (2001), Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation; Science, 292 468 3) Hamada et al. (2009), Synthesis and activity of N-oxalylglycine and it’s derivatives as jumonji C-domain-containing histone lysine demethylase inhibitors; Bioorg. Med. Chem. Lett., 19 2852 4) Lomb et al. (2009), Prolyl hydroxylase inhibitors depend on extracellular glucose and hypoxia-inducible factor (HIF)-2alpha to inhibit cell death caused by nerve growth factor deprivation: evidence that HIF-2alpha has a role in NGF-promoted survival of sympathetic neurons; Mol. Pharmacol., 75 1198 5) Xie et al. (2012), PHD3-dependent hydroxylation of HCLK2 promotes the DNA damage response; J. Clin. Invest., 122 2827
-20°C (protect from light)
TARGET: Prolyl hydroxylase; Protein demethylase -- PATHWAY: Redox; Apoptosis inhibitor; DNA damage; p53; Chromatin; Post-translational modification -- RESEARCH AREA: Cell death; Neuroscience; Oxidative stress -- DISEASE AREA: Neurodegeneration